Resistin Contribution to Cardiovascular Risk in Chronic Kidney Disease Male Patients

Background: Resistin is a molecule that belongs to the Resistin-Like Molecules family (RELMs), the group of proteins taking part in inflammatory processes. Increased resistin concentrations are observed in cardiovascular complications. Resistin contributes to the onset of atherosclerosis and intensifies the atherosclerotic processes. The aim of this study was to investigate the relationship between resistin and cardiovascular (CV) risk in men with chronic kidney disease (CKD) not treated with dialysis. Materials and Methods: One hundred and forty-two men were included in the study: 99 men with eGFR lower than 60 mL/min/1.73 m(2) and 43 men with eGFR >= 60 mL/min/1.73 m(2). CV risk was assessed. Serum resistin, tumor necrosis factor-alpha (TNF-alpha) and plasminogen activator inhibitor-1 (PAI-1) were measured among other biochemical parameters. Results: We observed that resistin concentrations were significantly higher in patients with CKD compared to individuals with eGFR lower than 60 mL/min/1.73 m(2) (p = 0.003). In CKD, after estimating the general linear model (GLM), we found that resistin is associated with CV risk (p = 0.026) and PAI-1 serum concentrations (0.012). The relationship of PAI-1 with resistin depends on the level of CV risk in CKD (p = 0.048). Conclusions: Resistin concentrations rise with the increase of CV risk in CKD patients and thus resistin may contribute to the progression of cardiovascular risk in this group of patients. The relationship between resistin and CV risk is modified by PAI-1 concentrations.

Automated summary

This study investigated the relationship between resistin and cardiovascular risk in men with chronic kidney disease (CKD) not treated with dialysis. The results showed that resistin concentrations were significantly higher in CKD patients and resistin may contribute to the progression of cardiovascular risk in this group of patients. Additionally, the relationship between resistin and CV risk is modified by PAI-1 concentrations.